Contact this trialFirst, we need to learn more about you.
Virus Therapy
GT90001 + Nivolumab for Liver Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new combination therapy for people with liver cancer who have not responded well to other treatments. The proposed dose is GT90001 7 mg/kg in combination with Nivolumab 240 mg, given as an infusion every two weeks. A total of 105 subjects will be enrolled in the study.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.